Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Finished Goods (2022 - 2025)

Fennec Pharmaceuticals' Finished Goods history spans 4 years, with the latest figure at $1.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 47.64% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Dec 2025, up 47.64%, and an annual FY2025 reading of $1.6 million, up 47.64% over the prior year.
  • Finished Goods for Q4 2025 was $1.6 million at Fennec Pharmaceuticals, down from $2.5 million in the prior quarter.
  • The five-year high for Finished Goods was $2.5 million in Q3 2025, with the low at $576000.0 in Q4 2022.
  • Average Finished Goods over 4 years is $1.6 million, with a median of $1.6 million recorded in 2025.
  • Year-over-year, Finished Goods skyrocketed 274.31% in 2023 and then tumbled 50.83% in 2024.
  • Tracing FENC's Finished Goods over 4 years: stood at $576000.0 in 2022, then skyrocketed by 274.31% to $2.2 million in 2023, then tumbled by 50.83% to $1.1 million in 2024, then skyrocketed by 47.64% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Finished Goods are $1.6 million (Q4 2025), $2.5 million (Q3 2025), and $2.2 million (Q2 2025).